Sanofi's Lemtrada wins Brazilian OK; Novartis poster campaign highlights meningitis; Selfies help raise millions for cancer charities;

> ViiV Healthcare has announced the next round of its Positive Action Southern Initiative, which works with community organizations in Alabama, Georgia, Louisiana and Mississippi to support linkages to HIV/AIDS care and treatment among at-risk populations. Release

> Sanofi's ($SNY) Genzyme has won approval from Brazil's national health surveillance agency for multiple sclerosis drug Lemtrada. Release

> Eli Lilly ($LLY) has launched an online training tool to help patient advocates understand health technology assessment. More

> Novartis ($NVS) has launched a poster campaign in Germany to raise public awareness about meningococcal bacteria and vaccines. More

> Astellas has won marketing approval in Japan for its prostate cancer treatment Xtandi. Release

> Novartis ($NVS) is launching a Lucentis prefilled syringe in Europe, which it says will reduce the risk of adverse events from nonsterile conditions. Release

> England has added Celgene's ($CELG) Abraxane, Roche's ($RHHBY) Avastin and Exelixis's Cometriq to its Cancer Drugs Fund, which offers access to meds not routinely funded by its National Health Service. More

> Experts say health apps are the "key to patient-centered healthcare." More

> Axxess Pharma has launched two websites to market its muscle supplements; the company believes they will help generate an additional $1.5 million in gross monthly sales within 45 days. Release

And Finally... The hashtag #nomakeupselfie has helped raise more than £8 million ($13.2 million) for cancer charities, with women posting photos highlighting the risks of cancer and then donating to a range of charities. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?